Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | AZD9592 |
| Trade Name | |
| Synonyms | AZD 9592|AZD-9592 |
| Drug Descriptions |
AZD9592 is an antibody-drug conjugate (ADC) comprising a bispecific antibody that targets EGFR and MET conjugated to a topoisomerase 1 inhibitor, which potentially leads to tumor cell apoptosis and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 5737, Cancer Res (2023) 83 (7_Supplement): 5736). |
| DrugClasses | EGFR Antibody 72 MET Antibody 37 |
| CAS Registry Number | NA |
| NCIT ID | C192091 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| AZD9592 | AZD9592 | 0 | 1 |
| AZD9592 + Bevacizumab + Fluorouracil + Leucovorin | AZD9592 Bevacizumab Fluorouracil Leucovorin | 0 | 1 |
| AZD9592 + Osimertinib | AZD9592 Osimertinib | 0 | 1 |